The multikinase inhibitor sorafenib, which is one of the few systemic treatment options for advanced HCC, blocks tumor cell proliferation by inhibiting the activity of kinases in the Ras/Raf/MEK/ERK signaling pathway and inhibiting angiogenesis through targeting of c-Kit, VEGFR, PDGFR-β, and other tyrosine kinases, although its clinical efficacy is restricted by drug resistance [32, 33]. Here, KDR is linked to neoplasm.